Citurgia Biochem Q1 FY27 Results (BSE: 506373)
Signal: Steady quarter
The read
The key trajectory remains non-operating: revenue stayed at ₹0 lakh for the current, preceding and year-ago quarters, while the loss narrowed to ₹8.20 lakh from ₹25.82 lakh sequentially primarily because employee benefits fell to ₹3.00 lakh from ₹5.94 lakh and other expenses to ₹0.05 lakh from ₹14.15 lakh; this is cost reduction rather than a business recovery.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹0 Cr | N/A | N/A |
| EBIT | ₹-0.08 Cr | 0.0% | |
| Net profit | ₹-0.08 Cr | 0.0% | |
| EPS | ₹0 | N/A | |
| EBIT margin | N/A |
P&L walk
Standalone revenue was ₹0 lakh, while ₹8.20 lakh of expenses produced an ₹8.20 lakh loss; the sequential improvement came mainly from lower employee and other expenses, not from operating growth.
Key positives
- Loss narrowed to ₹8.20 lakh from ₹25.82 lakh in the preceding quarter, led by lower employee benefits expense of ₹3.00 lakh versus ₹5.94 lakh and other expenses of ₹0.05 lakh versus ₹14.15 lakh.
Key concerns
- Revenue remained ₹0 lakh for the quarter and the comparable quarters, providing no evidence of a functioning chemicals operating franchise.
- The ₹8.20 lakh loss was still fully expense-driven, with depreciation of ₹5.15 lakh and employee benefits of ₹3.00 lakh despite zero revenue.
- Sequential loss improvement reflects cost compression rather than revenue, volume, realisation or utilisation growth.
Research and educational content only. Not investment advice.